Logo image of CBIO

CRESCENT BIOPHARMA INC (CBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CBIO - KYG2545C1042 - Common Stock

13.17 USD
+0.1 (+0.77%)
Last: 12/8/2025, 4:42:12 PM
13.6 USD
+0.43 (+3.26%)
After Hours: 12/8/2025, 4:42:12 PM
Fundamental Rating

1

Taking everything into account, CBIO scores 1 out of 10 in our fundamental rating. CBIO was compared to 531 industry peers in the Biotechnology industry. The financial health of CBIO is average, but there are quite some concerns on its profitability. CBIO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CBIO had negative earnings in the past year.
In the past year CBIO has reported a negative cash flow from operations.
CBIO had negative earnings in each of the past 5 years.
In the past 5 years CBIO always reported negative operating cash flow.
CBIO Yearly Net Income VS EBIT VS OCF VS FCFCBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

The Return On Assets of CBIO (-341.52%) is worse than 94.35% of its industry peers.
The Return On Equity of CBIO (-712.87%) is worse than 78.72% of its industry peers.
Industry RankSector Rank
ROA -341.52%
ROE -712.87%
ROIC N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
CBIO Yearly ROA, ROE, ROICCBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -200 -400 -600

1.3 Margins

CBIO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBIO Yearly Profit, Operating, Gross MarginsCBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

5

2. Health

2.1 Basic Checks

CBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
CBIO has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for CBIO has been reduced compared to 5 years ago.
CBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CBIO Yearly Shares OutstandingCBIO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
CBIO Yearly Total Debt VS Total AssetsCBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

Based on the Altman-Z score of -52.65, we must say that CBIO is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of CBIO (-52.65) is worse than 93.41% of its industry peers.
CBIO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -52.65
ROIC/WACCN/A
WACC8.78%
CBIO Yearly LT Debt VS Equity VS FCFCBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 1.92 indicates that CBIO should not have too much problems paying its short term obligations.
CBIO's Current ratio of 1.92 is on the low side compared to the rest of the industry. CBIO is outperformed by 77.97% of its industry peers.
A Quick Ratio of 1.92 indicates that CBIO should not have too much problems paying its short term obligations.
CBIO's Quick ratio of 1.92 is on the low side compared to the rest of the industry. CBIO is outperformed by 76.27% of its industry peers.
Industry RankSector Rank
Current Ratio 1.92
Quick Ratio 1.92
CBIO Yearly Current Assets VS Current LiabilitesCBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 34.09% over the past year.
CBIO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -87.50%.
CBIO shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -90.05% yearly.
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -47.97% on average over the next years. This is quite bad
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-6.84%
EPS Next 2Y-266.79%
EPS Next 3Y-114.78%
EPS Next 5Y-47.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CBIO Yearly Revenue VS EstimatesCBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2020 2021 2022 2023 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
CBIO Yearly EPS VS EstimatesCBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -50 -100 -150

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CBIO. In the last year negative earnings were reported.
Also next year CBIO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBIO Price Earnings VS Forward Price EarningsCBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBIO Per share dataCBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -2 -4 -6

4.3 Compensation for Growth

A cheap valuation may be justified as CBIO's earnings are expected to decrease with -114.78% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-266.79%
EPS Next 3Y-114.78%

More info and screens

0

5. Dividend

5.1 Amount

CBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CRESCENT BIOPHARMA INC

NASDAQ:CBIO (12/8/2025, 4:42:12 PM)

After market: 13.6 +0.43 (+3.26%)

13.17

+0.1 (+0.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/bmo
Earnings (Next)02-09 2026-02-09/amc
Inst Owners70.86%
Inst Owner Change5.27%
Ins Owners0.09%
Ins Owner Change132.58%
Market Cap182.93M
Revenue(TTM)10.00K
Net Income(TTM)-37.88M
Analysts86.15
Price Target27.03 (105.24%)
Short Float %4.95%
Short Ratio6.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.92%
PT rev (3m)3.92%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-6.03%
EPS NY rev (3m)-50.2%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 34.43
P/tB 34.43
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-7.8
Fwd EYN/A
FCF(TTM)-2.24
FCFYN/A
OCF(TTM)-2.24
OCFYN/A
SpS0
BVpS0.38
TBVpS0.38
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -341.52%
ROE -712.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-171.03%
ROA(5y)-123.21%
ROE(3y)-305.92%
ROE(5y)-207.06%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 28.41%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.92
Quick Ratio 1.92
Altman-Z -52.65
F-Score2
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)26.82%
Cap/Depr(5y)22.05%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y-6.84%
EPS Next 2Y-266.79%
EPS Next 3Y-114.78%
EPS Next 5Y-47.97%
Revenue 1Y (TTM)-87.5%
Revenue growth 3Y-90.05%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y17.22%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y10.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.84%
OCF growth 3YN/A
OCF growth 5YN/A

CRESCENT BIOPHARMA INC / CBIO FAQ

Can you provide the ChartMill fundamental rating for CRESCENT BIOPHARMA INC?

ChartMill assigns a fundamental rating of 1 / 10 to CBIO.


Can you provide the valuation status for CRESCENT BIOPHARMA INC?

ChartMill assigns a valuation rating of 0 / 10 to CRESCENT BIOPHARMA INC (CBIO). This can be considered as Overvalued.


Can you provide the profitability details for CRESCENT BIOPHARMA INC?

CRESCENT BIOPHARMA INC (CBIO) has a profitability rating of 0 / 10.


Can you provide the financial health for CBIO stock?

The financial health rating of CRESCENT BIOPHARMA INC (CBIO) is 5 / 10.


Can you provide the expected EPS growth for CBIO stock?

The Earnings per Share (EPS) of CRESCENT BIOPHARMA INC (CBIO) is expected to decline by -6.84% in the next year.